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Abstract 
NBS1, also known as NBN, plays an important role in maintaining genomic stability. 
Interestingly, rs2735383 G>C, located in a microRNA binding site in the 3’-untranslated region 
(UTR) of NBS1, was shown to be associated with increased susceptibility to lung and colorectal 
cancer. However, the relation between rs2735383 and susceptibility to breast cancer is not yet 
clear. Therefore, we genotyped rs2735383 in 1,170 familial non-BRCA1/2 breast cancer cases 
and 1,077 controls using PCR-based restriction fragment length polymorphism (RFLP-PCR) 
analysis, but found no association between rs2735383CC and breast cancer risk (OR=1.214, 95% 
CI=0.936-1.574, P=0.144). Because we could not exclude a small effect size due to a limited 
sample size, we further analyzed imputed rs2735383 genotypes (r
2
>0.999) of 47,640 breast 
cancer cases and 46,656 controls from the Breast Cancer Association Consortium (BCAC). 
However, rs2735383CC was not associated with overall breast cancer risk in European 
(OR=1.014, 95% CI=0.969-1.060, P=0.556) nor in Asian women (OR=0.998, 95% CI=0.905-
1.100, P=0.961). Subgroup analyses by age, age at menarche, age at menopause, menopausal 
status, number of pregnancies, breast feeding, family history and receptor status also did not 
reveal a significant association. This study therefore does not support the involvement of the 
genotype at NBS1 rs2735383 in breast cancer susceptibility.     
10 
 
Introduction  
The DNA damage response (DDR) pathway maintains the stability of the human genome via a 
complex network of pathways integrating signal transduction, regulation of the cell cycle and 
repair of DNA. Double-strand breaks (DSBs), a particularly severe form of DNA damage, arise 
as a consequence of cell replication, programmed DNA rearrangements (i.e. meiosis and VDJ 
recombination) and exposure to carcinogens. When left unrepaired, DSBs may cause genomic 
instability, cell death and cancer
1,2
. In fact, mutations in genes involved in DSB repair, but also 
in the DDR pathway in general, are involved in the etiology of many human cancers. The two 
major repair pathways that mediate the repair of DSBs are the template-mediated homologous 
recombination repair pathway and the more error-prone non-homologous end-joining pathway
3,4
. 
The MRE11/RAD50/NBS1 complex is an important regulator of DSB repair through these 
pathways as this complex not only acts as a sensor of DSBs, but also recruits and activates the 
ATM protein to the break and activates it
5
. Activation of ATM, the central mediator of response 
to DSBs, initiates a cascade of signaling pathways involved in cell cycle checkpoint control, 
DNA repair and, when necessary, apoptosis by phosphorylation of p53, CHEK2, BRCA1, 
FANCD2 and NBS1 amongst others
6
. 
 The DDR plays an important role in susceptibility to breast cancer. In fact, all of the 
currently identified high- and moderate-risk breast cancer genes (i.e. BRCA1, BRCA2, CHEK2, 
ATM, NBS1 and PALB2) are involved in DNA repair
7,8
. As the majority of familial breast cancer 
risk is not yet attributable to known risk genes, this makes other genes encoding proteins 
involved in the DDR pathway attractive candidates for breast cancer susceptibility genes. The 
recent identification of the early DNA damage response gene MCPH1as a novel breast cancer 
susceptibility gene illustrates that this hypothesis still holds
9
.   
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In this respect, the NBS1 gene is located at chromosome 8q21 and bi-allelic germline 
mutations in NBS1 cause the chromosomal instability syndrome Nijmegen breakage syndrome
10
. 
In addition, heterozygous carriers of NBS1 mutations are at an increased risk to develop several 
types of cancer
11
. The NBS1 c.657del5 founder mutation is the most prevalent mutation 
implicated in Nijmegen breakage syndrome (i.e. 90%) and has its origin in the Slavic 
population
12
. The mutation confers an overall 2.5- to 3-fold increased cancer risk and is 
associated with increased risk for breast cancer, prostate cancer and lymphoma specifically
13
. 
Two other NBS1 mutations implicated in Nijmegen breakage syndrome are p.I171V and 
p.R215W. Although both mutations associate with an overall cancer risk of 4-fold and 2-fold, 
respectively, there does not seem to be an increased risk to develop breast cancer specifically
13
. 
Besides the rare Nijmegen breakage syndrome-associated mutations, two common 
variants in NBS1 (i.e. p.E185Q; rs1805794 and c.2265+541G>C; rs2735383) have also been 
reported to be associated with risks for several cancer types. Recent meta-analyses for rs1805794 
have, however, shown that this variant does not associate with breast cancer risk
13-16
, while 
associations with lung cancer and urinary system cancer are still inconclusive
13,16-18
. The 
functional variant rs2735383, localized in in the 3’ UTR of NBS1, has been shown to modulate 
the binding ability of microRNA-629 in lung cancer cells and microRNA-509-5p in colorectal 
cancer cells, affect NBS1 transcriptional activity and decrease NBS1 mRNA and NBS1 protein 
levels
19,20
. Although rs2735383 has been associated with an increased risk of lung cancer and 
colorectal cancer
13,20
, its association with breast cancer risk is yet unclear. For this reason, we 
assessed whether NBS1 rs2735383 is associated with breast cancer risk in the Rotterdam Breast 
Cancer Study (RBCS) by RFLP-PCR and in 45 studies of BCAC through imputation of the 
iCOGS array
24
. 
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Results 
To evaluate the association between NBS1 rs2735383 and breast cancer risk, we analyzed NBS1 
rs2735383 by RFLP-PCR in 1,269 non-BRCA1/2 familial breast cancer patients and 1,159 
controls from RBCS. Since genetic risk factors are usually enriched in familial/early-onset breast 
cancer cases, specifically selecting these breast cancer patients improves statistical power. 
Among the cases, 516 had the GG genotype, 507 had the GC genotype and 147 had the CC 
genotype at rs2735383 (minor allele frequency (MAF)=0.342). Among the controls, 462 had the 
GG genotype, 501 had the GC genotype and 114 had the CC genotype (MAF=0.338). For both 
cases and controls, the genotypes of rs2735383 were in Hardy-Weinberg equilibrium (HWE). 
Because rs2735383 CC was associated with an increased risk of lung cancer and colorectal 
cancer under a recessive genetic model
13,20
, we analyzed the association of rs2735383 with breast 
cancer in a similar way. However, rs2735383 was not significantly associated with the risk of 
breast cancer (OR=1.214, 95% CI=0.936-1.574, P=0.144; Table 1). In this respect, the lung 
cancer risk conferred by the rs2735383 CC genotype had been associated with an OR of 1.28 
(95% CI=1.21-1.46, P<0.001), whereas the colorectal cancer risk had been associated with an 
OR of 1.55 (95% CI=1.27-1.94, P<10
-4
)
13,20
. Here, we do not observe a similar effect size for 
breast cancer as for lung and colorectal cancer. However, RBCS is underpowered to detect effect 
sizes smaller than those observed for lung cancer (i.e. OR<1.28). Therefore, we cannot exclude 
rs2735383 CC is associated with breast cancer, but confers a smaller risk.  
For this reason we analyzed NBS1 rs2735383 in BCAC studies through imputation. Since 
we had data available for RBCS on rs2735383 from both the PCR-based RFLP and from 
imputation, we first evaluated the concordance between the two methods. In total, from 1,313 
13 
 
samples (i.e. 646 cases and 667 controls) we had genotypes for rs2738353 available from both 
RFLP-PCR and imputation. Importantly, the agreement between the two methods was 97.1% 
(i.e. concordance in 1,275 of 1,313 samples, r
2
=0.933) and was similar among cases and controls 
(i.e. 98.1% versus 96.1%). Moreover, case-control ORs for imputed data were comparable to 
ORs obtained by RFLP-PCR (OR=1.14, 95% CI=0.80-1.62 versus OR=1.17, 95% CI=0.83-
1.66). Therefore, we used the imputed data on rs2735383 to evaluate further its association with 
breast cancer risk.  
For the overall analysis in Europeans we had 41,915 cases and 40,042 controls available 
from 36 case-control studies. However, rs2735383 was not associated with breast cancer risk in 
Europeans, neither under a recessive genetic model (OR=1.014, 95% CI=0.969-1.060, P=0.556; 
Table 2 and Fig. 1), nor under a dominant (OR=1.006, 95% CI=0.978-1.035, P=0.684; Table 2) 
or additive model (per allele OR=1.000, 95% CI=0.979-1.021, P=0.984; Table 2). Because the 
association with increased lung and colorectal cancer risk was observed in the Asian 
population
13,20
, we also performed the same analysis in the nine Asian BCAC studies. In total, 
we had 5,725 cases and 6,614 controls available for this analysis from nine case-control studies. 
Also in Asians we did not find any association between rs2735383 and breast cancer risk for 
either the recessive (OR=0.998, 95% CI=0.905-1.100, P=0.961; Table 2 and Fig. 1), dominant 
(OR=0.995, 95% CI=0.922-1.074, P=0.900; Table 2) or additive genetic model (per allele 
OR=0.997, 95% CI=0.946-1.050, P=0.911; Table 2). These results imply that NBS1 rs2735383 is 
not associated with an increased risk to develop invasive breast cancer.    
A previous study had shown that rs2735383 may be associated with breast cancer risk in 
women > 50 years,  women with age at menarche >13 years, women with premenopausal status, 
women with number of abortions ≤ 2 and women who have breast fed, but not by age at 
14 
 
menopause, number of pregnancies and family history
21
. Therefore, to exclude that an 
association of rs2735383 with breast cancer risk exists in a particular subgroup of individuals or 
breast cancer patients, we performed subgroup analysis according to age, age at menarche, age at 
menopause, menopausal status, number of full-term pregnancies, breast feeding, family history 
and receptor status. We did, however, not find any association between the genotype at 
rs2735383 and the risk of breast cancer in any of these subgroups for the recessive genetic model 
(Table 3). Also for the dominant and additive genetic models we found no association between 
the genotype at rs2735383 and breast cancer risk that would withstand multiple testing correction 
(Supplementary Tables S1 and S2). NBS1 rs2735383 is thus not associated with the risk for 
breast cancer, either in the overall analyses or in specific subgroups.  
 
Discussion  
The CC genotype of the common variant rs2735383 in the 3’UTR of NBS1 has been shown to be 
associated with an increased cancer risk, specifically for lung and colorectal cancer (lung cancer: 
OR=1.28, 95% CI=1.21-1.46, P<0.001 and colorectal cancer: OR=1.55, 95% CI=1.27-1.94, 
P<10
-4
)
13,20
. In the current study, we evaluated the association of NBS1 rs2735383 with breast 
cancer risk. We found that the CC genotype of rs2735383 did not confer an increased breast 
cancer risk, neither in the overall analyses nor in the subgroup analyses.   
In agreement with these results, a small study by Han et al. consisting of 239 
premenopausal breast cancer patients and 477 matched controls from the Nurses’ Health Study II 
showed that rs2735383 did not associate with breast cancer risk under an additive genetic model 
(OR=0.92, 95% CI=0.72-1.16, P=0.469)
22
. Moreover, the study of Wu et al. consisting of 450 
breast cancer patients and 450 cancer-free controls from the Henan Province in China also found 
15 
 
no association with overall breast cancer risk
21
. However, after stratification according to 
reproductive factors, rs2735383 CC was found to be associated with an increased breast cancer 
risk for women > 50 years, women with age at menarche >13 years, women with premenopausal 
status, women with number of abortions ≤ 2 and women who have breast fed, but not by age at 
menopause, number of pregnancies and family history
21
. In the current study we therefore also 
performed subgroup analysis by age, age at menarche, age at menopause, menopausal status, 
number of full-term pregnancies, breast feeding, family history and receptor status, but did not 
find any association between rs2735383 and risk of breast cancer in any of these subgroups that 
would withstand multiple testing correction. We thus could not replicate the earlier positive 
findings in women > 50 years, women with age at menarche >13 years, premenopausal women 
and women who have breast fed. A possible, but not very likely, explanation for the difference in 
outcome between the studies may be the European versus Asian ethnicity. In the current study 
we chose to perform the subgroup analysis only in the European studies and not the Asian 
studies as this made sure that we had sufficient power in the subgroup analysis to identify 
smaller effects of rs2735383 on breast cancer risk. In this respect, a more plausible explanation 
would be that subgroup analyses, especially in a small study population (i.e. 450 cases and 450 
controls in the study of Wu et al.), could have easily given rise to false positive findings. 
Therefore, one should be careful when reporting positive findings from multiple small subgroup 
comparisons and always use appropriate levels of statistical significance
23
. Unfortunately, in the 
study from Wu et al. there is no mention of multiple testing correction. 
It was found that the rs2735383CC genotype significantly decreased the expression of the 
NBS1 gene through either binding of microRNA-629 to the 3’-UTR of NBS1 gene in lung cancer 
cells or the binding of microRNA-509-5p to the 3’-UTR of NBS1 gene in colorectal cancer 
16 
 
cells
19,20
. Since low expression of NBS1 may reduce the efficiency of DSB repair, this way the 
rs2735383CC genotype likely confers an increased lung and colorectal cancer risk. According to 
our study, however, the rs2735383CC genotype does not confer an increased breast cancer risk. 
Considering that in lung and colorectal cancer cells different microRNAs appear to be 
downregulating NBS1 expression, tissue specific expression of these microRNAs may likely play 
a role. Besides microRNA-509 and microRNA-629, the C allele at rs2735383 has also been 
predicted to enhance the binding of microRNA-499 and microRNA-508 to the 3’UTR of NBS121. 
However, if these microRNAs are not expressed in normal breast tissue, the CC genotype of 
rs2735383 will not associate with breast cancer risk as NBS1 cannot be downregulated by any of 
these microRNAs. At least in breast cancer cells, none of these microRNAs, except microRNA-
629, are expressed at substantial levels (source: TCGA Research Network; 
http://cancergenome.nih.gov/). Since microRNAs are often deregulated between normal tissue 
and cancer tissue, this does not necessarily represent the situation in normal breast cells. Thus, 
further evaluation of the miRNA expression levels in normal (breast) tissue, but also their 
correlation with the genotype at rs2735383 should provide more insight for the tissue specificity 
of rs2735383 and cancer risk. 
Importantly, in contrast to lung and colorectal cancer susceptibility, the results of this 
study do not support the presence of an association (i.e. OR>1.04 for Europeans and OR>1.11 
for Asians) between the genotype at rs2735383 in the 3’UTR of NBS1 and breast cancer 
susceptibility. 
 
Materials and Methods 
Study population 
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RBCS cases (N=1,269) came from the database of the Clinical Genetics Department at Erasmus 
University Medical Centre in Rotterdam, representing the Southwestern part of the Netherlands. 
First, we selected families that presented with at least two cases of female breast cancer or at 
least one case of female breast cancer and one case of ovarian cancer in first- or second-degree 
relatives. In addition, at least one of these two cases needed to be diagnosed before the age of 60. 
For each selected family, the youngest breast cancer patient who had been tested for BRCA1 and 
BRCA2 was then assigned to be the index case and included in RBCS. Furthermore, breast 
cancer cases were also included if they were diagnosed either before the age of 40 years with 
unilateral breast cancer or before 50 years of age with bilateral breast cancer and did not report a 
family history of either breast or ovarian cancer in a first or second degree relative. All index 
cases and their tested relatives did not carry a BRCA1 or BRCA2 mutation. The median age of the 
RBCS cases was 44 years (range 18-92 years). RBCS controls (N=1,159) came from the same 
database and geographic location as the RBCS cases and included women from cystic fibrosis 
families who were either spouses of individuals at risk of being carrier of a CFTR mutation or 
individuals who were tested negative for a CFTR mutation. The median age of the RBCS 
controls was 41 years (range 10-97 years).   
BCAC consists of case-control studies of unrelated women
24
. For the purpose of the 
current analyses, only studies with participants of European and Asian ancestry were included, 
resulting in a total of 45 case-control studies (Supplementary Table S3). Studies with participants 
of African ancestry (i.e. two studies) were not included because power in the analyses would be 
low due to a relatively low MAF (i.e. 0.123) and small amount of cases (i.e. 1,046). Each study 
was approved by its relevant governing research ethics committee and all study participants 
provided written informed consent. The experimental protocol was approved by the Medical 
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Ethical Committee of the Erasmus Medical Center Rotterdam and the study was carried out in 
accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the 
Netherlands (http://www.fmwv.nl). Following genotyping on the iCOGS array
24
, quality control 
exclusions (described below), and analysis-specific exclusions, data from the following women 
were available for analysis: 47,640 patients with invasive breast cancer and 46,656 controls, 
totaling 94,296 BCAC participants.  
 
PCR-based RFLP analysis  
A 324 bp fragment of the 3’UTR of NBS1 including rs2735383 was amplified in a duplex PCR 
reaction together with a 713 bp fragment of the LRRC4 gene. Primers for NBS1 and LRRC4 were 
present in the PCR reaction at a final concentration of 0.25 and 1 µM, respectively, and 
sequences are available in Supplementary Table S4. The amplified LRRC4 fragment served as an 
internal digestion control and generated two fragments of 549 and 164 bp upon complete 
digestion with ScfI (New England Biolabs, Frankfurt am Main, Germany). The 324 bp amplified 
NBS1 fragment was only digested when the major G allele was present at rs2735383, thereby 
generating two fragments of 233 and 91 bp. Thus upon successful digestion with ScfI, samples 
with rs2735383 GG generated four fragments, samples with rs2735383 GC generated five 
fragments and samples with rs2735383 CC generated three fragments (Fig. 2).    
 
iCOGS genotyping and imputation 
Genotyping of BCAC studies was performed previously using the custom iCOGS Illumina 
Infinium iSelect BeadChip
24
. Briefly, DNA samples from 114,255 BCAC participants were 
genotyped, along with HapMap2 DNAs for European, African, and Asian populations. Raw 
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intensity data files underwent centralized genotype calling and quality control
24
. The HapMap2 
samples were used to identify women with predicted European and Asian ancestry by 
performing  principal component (PC) analysis using a set of over 37,000 unlinked markers
25
. 
Nine European PCs and two Asian PCs were found to control adequately for residual population 
stratification in BCAC data. Samples with a low conversion rate, extreme heterozygosity, non-
female sex, or one of a first-degree relative pair were excluded. Variants were excluded if they 
were monomorphic or had a call rate <95% (i.e. when MAF >0.05) or <99% (i.e. when MAF 
<0.05), deviation from HWE (i.e. P <10-7), or >2% duplicate discordance. 
Imputation of genotypes was performed using 1000 Genomes Project data (v3 April 2012 
release) as the reference panel
26,27
. To improve computation efficiency we used a two-step 
procedure which involved pre-phasing by chromosome and by chunk using SHAPEIT software 
in the first step
28
 and imputation of the phased data using IMPUTE version 2 software in the 
second
29
. NBS1 rs2735383 was imputed with an imputation r
2 
> 0.999 in both Europeans and 
Asians.  
 
Statistical analyses 
The association between NBS1 rs2735383 and invasive breast cancer risk was evaluated by 
logistic regression analysis providing ORs and 95% CIs.  In the analyses of BCAC studies, ORs 
were adjusted for study, age, and PCs. In the analyses of RBCS, ethnicity was not a confounding 
factor thus reported ORs were unadjusted for PCs. For the European and Asian BCAC studies, 
we additionally performed study-specific logistic regression analysis adjusting for age and PCs, 
and pooled the log ORs in a fixed-effects meta-analysis. Subgroup analyses within the European 
BCAC studies were based on age (i.e. ≤ 50 years and > 50 years), age at menarche (i.e. ≤ 13 
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years and > 13 years), age at menopause (i.e. ≤ 50 years and > 50 years), menopausal status (i.e. 
premenopausal and postmenopausal), number of full-term pregnancies (i.e. ≤ 2 and > 2), breast 
feeding (i.e. no and yes), first-degree family history of breast cancer and receptor status (i.e. ER 
positive, ER negative and triple negative). Clinical and demographic characteristics of the BCAC 
cases are presented in Supplementary Table S5. Association between NBS1 rs2735383 and the 
clinical and demographic characteristics were evaluated using a 2 test. All P-values were two-
sided and P<0.05 was considered to be statistically significant after correction for multiple 
testing by the Bonferroni procedure. Logistic regression analyses were performed using SPSS 
statistics version 23 (IBM Corporation, Armonk, NY) and fixed-effects meta-analyses using 
Stata version 13 (StataCorp, College Station, TX).  
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Legends to Figures 
 
Figure 1. Forest plots for the association between rs2735383 and breast cancer risk. A) for 
the 36 European BCAC studies and B) for the nine Asian BCAC studies. Study-specific ORs 
(squares) were from a recessive genetic model and adjusted by age and PCs. Overall or pooled 
ORs (diamonds) were from a fixed-effects meta-analysis. 
 
Figure 2. Microchip electrophoresis of the RFLP-PCR products of 23 RBCS cases. After 
PCR amplification of NBS1 and LRRC4 fragments (i.e. 324 and 713 bp), digestion with SfcI 
generated four fragments (i.e. 549, 233, 164 and 91 bp) for samples with rs2735383 GG 
genotypes, five fragments (i.e. 549, 324, 233, 164 and 91 bp) for samples with rs2735383 GC 
genotypes and three fragments (i.e. 549, 324 and 164 bp) for samples with rs2735383 CC 
genotypes. UM, upper marker; LM, lower marker. 
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Table 1 Association of NBS1 rs2735383 with breast cancer risk in the RBCS study   
 
Genetic model N Controls N Cases OR (95% CI) P-value 
Recessive     
     GG + GC 963 1023 1  
     CC 114 147 1.214 (0.936-1.574) 0.144 
 1077 1170   
 
N, number of; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.  
39 
 
Table 2 Association of NBS1 rs2735383 with overall breast cancer risk in the European and 
Asian BCAC studies 
 
Ethnicity Genetic model 
N  
Controls 
N  
Cases 
MAF 
Controls 
MAF 
Cases OR (95% CI)* P-value* 
European  40,0042 41,915 33.44% 33.39%   
 Recessive     1.014 (0.969-1.060) 0.556 
 Dominant     1.006 (0.978-1.035) 0.684 
 Additive     1.000 (0.979-1.021) 0.984 
Asian  6,614 5,725 40.71% 40.58%   
 Recessive     0.998 (0.905-1.100) 0.961 
 Dominant     0.995 (0.922-1.074) 0.900 
 Additive     0.997 (0.946-1.050) 0.911 
 
N, number of; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. 
*adjusted for age, study and principal components (PCs). In the European analyses nine PCs were added to the 
regression model and in the Asian analyses two PCs.  
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Table 3 Subgroup analysis of NBS1 rs2735383 and breast cancer risk in the European BCAC 
studies 
 
Subgroup 
N  
Controls 
N  
Cases 
MAF 
Controls 
MAF 
Cases OR (95% CI)* P-value* 
Age       
     ≤ 50 years 13,055 13,362 33.76% 33.41% 0.977 (0.899-1.062) 0.581 
     > 50 years 26,987 28,553 33.28% 33.38% 1.026 (0.971-1.084) 0.356 
Age at menarche       
     ≤ 13 years      14,312 13,843 33.72% 33.13% 0.984 (0.914-1.060) 0.677 
     > 13 years 8,964 8,095 32.65% 33.63% 1.077 (0.978-1.187) 0.131 
Age at menopause       
     ≤ 50 years 5,571 7,288 32,79% 33.43% 1.019 (0.906-1.146) 0.755 
     > 50 years 3,366 4,262 33.50% 33.24% 0.993 (0.855-1.154) 0.926 
Menopausal status       
     Premenopausal 8,974 7,412 33.66% 33.07% 0.981 (0.887-1.085) 0.715 
     Postmenopausal 19,648 17,353 33.39% 33.56% 1.007 (0.943-1.075) 0.844 
Number of full-term 
pregnancies       
     ≤ 2 21,008 19,722 33.53% 33.20% 1.004 (0.942-1.071) 0.893 
     > 2 8,258 7,327 33.26% 33.44% 1.032 (0.931-1.144) 0.549 
Breast feeding       
     No 6,849 6,805 33.36% 33.25% 0.988 (0.884-1.104) 0.828 
     Yes 11,947 12,709 33.68% 33.28% 0.978 (0.903-1.060) 0.594 
Family history       
     1st degree relative     
     with BC 23,648 4,119 33.21% 32.68% 0.990 (0.884-1.108) 0.859 
Receptor status       
     ER positive 39,699 25,959 33.47% 33.40% 1.021 (0.970-1.075) 0.427 
     ER negative 39,618 6,774 33.42% 32.90% 0.991 (0.908-1.082) 0.846 
     Triple negative 30,696 2,712 33.10% 32.04% 0.980 (0.847-1.134) 0.788 
 
N, number; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; ER, estrogen receptor; BC, breast 
cancer 
*recessive genetic model adjusted for age, study and nine principal components. 
